Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Mar 23;7(1):8–19. doi: 10.1089/pancan.2020.0021

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Peter Muscarella et al., 2021; Published by Mary Ann Liebert, Inc.

This Open Access article is distributed under the terms of the Creative Commons License [CC-BY] (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

FIG. 2. — Recurrence-free survival (A) and OS (B, C) based on Kaplan–Meier estimates of all enrolled subjects (ITT population) (A, B) or ITT subjects with R1 resection (C) from date of randomization. Black line, GI-4000; gray line, placebo; dashed black line, GI-4000 treated R1 IFNγ ELISpot responders. Circles, censored data. A single subject in the R1 placebo group was an IFNγ ELISpot responder and had an OS of 382 days. IFNγ, interferon-γ; ITT, intent-to-treat; OS, overall survival.